Treating multiple sclerosis with fingolimod or intramuscular interferon

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study

(2009) P. O'Connor et al.   NEUROLOGY

Emerging oral drugs for multiple sclerosis

(2008) Claudio Gasperini et al.   EXPERT OPINION ON EMERGING DRUGS

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

FTY720 modulates human oligodendrocyte progenitor process extension and survival

(2007) Veronique E. Miron et al.   ANNALS OF NEUROLOGY